Skip to main content

Table 2 Patient characteristics

From: Effect of pirfenidone on wound healing in lung transplant patients

Variable Pirfenidone
n = 17
Control
n = 13
Demographics
 Mean age, years (range) 67 (60-77) 65 (58-73)
 Female sex 2 (11.8) 3 (23.1)
 Mean BMI, kg/m2 (range) 25.7 (20.45-33.5) 26.9 (20.2-34.6)
 ECMO as bridge to transplant 2 (12) 1 (7.7)
 Inpatient prior to transplant 6 (35.3) 4 (30.8)
 Unilateral lung transplant 3 (17.6) 0 (0)
 Mean LAS (range) 46 (32-90) 57 (33-94)
Pre-transplant steroid use 8 7
 Prednisone ≤ 10 mg daily 10 (58.8) 6 (46.2)
 Prednisone > 10 mg daily 1 (5.9) 1 (7.7)
Baseline laboratory values
 Glucose > 180 mg/dL 0 (0) 0 (0)
 ALT > 55 units/L 1 (5.9) 0 (0)
 AST > 34 units/L 0 (0) 1 (7.7)
 AlkPhos > 150 units/L 0 (0) 0 (0)
 Albumin < 3.5 g/dL 2 (11.8) 3 (23.1)
 Bilirubin > 1.2 mg/dL 0 (0) 1 (7.7)
 Creatinine > 1.25 mg/dL 0 (0) 0 (0)
 Phosphorous < 2.4 mg/dL 0 (0) 2 (15.4)
Immunosuppressant therapy post-transplant
 High-dose steroid + taper 17 (100) 13 (100)
 Basiliximab 11 (64.7) 8 (61.5)
 Tacrolimus 17 (100) 13 (100)
 Cyclosporine 0 (0) 2 (15.4)
 Mycophenolate 17 (100) 12 (92.3)
 Rituximab 4 (23.5) 4 (30.8)
 Antithymocyte globulin 2 (11.8) 0 (0)
 Azathioprine 0 (0) 1 (7.7)
  1. All values expressed are n (%), unless otherwise indicated
  2. Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, ECMO extracorporeal membrane oxygenation, LAS lung allocation score